FDA-cleared Unyvero LRT Panel… what hospitalized pneumonia patients have been missing.
Pneumonia is a serious and life-threatening lower respiratory lung infection. Hospital-acquired pneumonia, a common nosocomial bacterial infection, is most prevalent in medical and surgical intensive care units, and a leading cause of death in critically ill patients.
Pneumonia increases the duration of hospitalization by an average of 5.5 days and adds significantly to the cost of hospital care by approximately $40,000. Diagnosis is difficult because radiological and clinical signs are inadequate and could be associated with various respiratory diseases.
Pneumonia patients are frequently over-treated empirically with broad-spectrum antibiotics due to delayed definitive diagnosis.
Evaluation of Curetis Unyvero Lower Respiratory Tract (LRT) Panel
David W. Craft, PhD, D(ABMM)
Professor of Pathology, PennState College of Medicine
Medical Director, Clinical Microbiology Laboratory, PennState Hershey Medical Center
ASM Microbe 2019
San Francisco, CA
The Unyvero LRT Panel
The FDA-cleared Unyvero LRT panel is a comprehensive panel with 29 clinically relevant bacterial targets and antibiotic resistance markers that cover more than 90% of the most common pathogens and atypical bacteria that cause pneumonia, providing clinicians with rapid diagnostic results to enable earlier targeted treatment and drive better patient outcomes.
Panel is designed to meet the clinical need for rapid diagnosis of critically ill patients suspected with pneumonia
Rapid pathogen ID and resistance gene detection enables earlier optimization of antibiotic therapy
Faster, appropriate treatment improves outcomes and reduces costs
Proven PCR technology
Automated, sample-to-answer performance achieved by end-point PCR and microarray detection, which sets Unyvero apart in its capability for high multiplexing to address a wide range of syndromic disease testing needs.
92.5% sensitivity, 97.4% specificity